U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C16H20N4O3S
Molecular Weight 348.42
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TORSEMIDE

SMILES

CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC2=CC=CC(C)=C2

InChI

InChIKey=NGBFQHCMQULJNZ-UHFFFAOYSA-N
InChI=1S/C16H20N4O3S/c1-11(2)18-16(21)20-24(22,23)15-10-17-8-7-14(15)19-13-6-4-5-12(3)9-13/h4-11H,1-3H3,(H,17,19)(H2,18,20,21)

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020136s023lbl.pdf

Torasemide is a pyridine-sulfonylurea type loop diuretic mainly used for the treatment of edema associated with congestive heart failure, renal disease, or hepatic disease. Also for the treatment of hypertension alone or in combination with other antihypertensive agents. It is also used at low doses for the management of hypertension. It is marketed under the brand name Demadex. Torasemide inhibits the Na+/K+/2Cl--carrier system (via interference of the chloride binding site) in the lumen of the thick ascending portion of the loop of Henle, resulting in a decrease in reabsorption of sodium and chloride. This results in an increase in the rate of delivery of tubular fluid and electrolytes to the distal sites of hydrogen and potassium ion secretion, while plasma volume contraction increases aldosterone production. The increased delivery and high aldosterone levels promote sodium reabsorption at the distal tubules, and by increasing the delivery of sodium to the distal renal tubule, torasemide indirectly increases potassium excretion via the sodium-potassium exchange mechanism. Torasemide's effects in other segments of the nephron have not been demonstrated. Thus torasemide increases the urinary excretion of sodium, chloride, and water, but it does not significantly alter glomerular filtration rate, renal plasma flow, or acid-base balance. Torasemide's effects as a antihypertensive are due to its diuretic actions. By reducing extracellular and plasma fluid volume, blood pressure is reduced temporarily, and cardiac output also decreases.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Demadex

Approved Use

Demadex is indicated for the treatment of edema associated with congestive heart failure, renal disease, or hepatic disease. Use of torsemide has been found to be effective for the treatment of edema associated with chronic renal failure. Demadex is indicated for the treatment of hypertension alone or in combination with other antihypertensive agents.

Launch Date

1993
Primary
Demadex

Approved Use

Demadex is indicated for the treatment of edema associated with congestive heart failure, renal disease, or hepatic disease. Use of torsemide has been found to be effective for the treatment of edema associated with chronic renal failure. Demadex is indicated for the treatment of hypertension alone or in combination with other antihypertensive agents.

Launch Date

1993
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
968.7 ng/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TORSEMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1549.9 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TORSEMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1561 ng × h/mL
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TORSEMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
3516 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TORSEMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4.4 h
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TORSEMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
4.5 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TORSEMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
10 mg 1 times / day multiple, oral
dose: 10 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
TORSEMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
400 mg 1 times / day multiple, oral
Highest studied dose
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
unhealthy
800 mg single, intravenous
Highest studied dose
Dose: 800 mg
Route: intravenous
Route: single
Dose: 800 mg
Sources:
unhealthy
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy
Disc. AE: Electrolyte depletion, Electrolyte depletion...
Other AEs: Hepatic coma, Tinnitus...
AEs leading to
discontinuation/dose reduction:
Electrolyte depletion
Electrolyte depletion
Hypokalemia
Other AEs:
Hepatic coma
Tinnitus
Hearing loss
Sources:
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy
Disc. AE: Dizziness, Headache...
AEs leading to
discontinuation/dose reduction:
Dizziness (0.1 - 0.5)
Headache (0.1 - 0.5)
Nausea (0.1 - 0.5)
Weakness (0.1 - 0.5)
Vomiting (0.1 - 0.5)
Hyperglycemia (0.1 - 0.5)
Urination abnormal NOS (0.1 - 0.5)
Hyperuricemia (0.1 - 0.5)
Hypokalemia (0.1 - 0.5)
Excessive thirst (0.1 - 0.5)
Hypovolemia (0.1 - 0.5)
Impotence (0.1 - 0.5)
Esophageal hemorrhage (0.1 - 0.5)
Dyspepsia (0.1 - 0.5)
Sources:
200 mg 1 times / day multiple, intravenous
Studied dose
Dose: 200 mg, 1 times / day
Route: intravenous
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy
Health Status: unhealthy
Sources:
AEs

AEs

AESignificanceDosePopulation
Hearing loss
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy
Hepatic coma
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy
Tinnitus
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy
Electrolyte depletion Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy
Electrolyte depletion Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy
Hypokalemia Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy
Dizziness 0.1 - 0.5
Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy
Dyspepsia 0.1 - 0.5
Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy
Esophageal hemorrhage 0.1 - 0.5
Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy
Excessive thirst 0.1 - 0.5
Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy
Headache 0.1 - 0.5
Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy
Hyperglycemia 0.1 - 0.5
Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy
Hyperuricemia 0.1 - 0.5
Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy
Hypokalemia 0.1 - 0.5
Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy
Hypovolemia 0.1 - 0.5
Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy
Impotence 0.1 - 0.5
Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy
Nausea 0.1 - 0.5
Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy
Urination abnormal NOS 0.1 - 0.5
Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy
Vomiting 0.1 - 0.5
Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy
Weakness 0.1 - 0.5
Disc. AE
200 mg 1 times / day multiple, oral
Recommended
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
unhealthy
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer






Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [Inhibition 100 uM]
yes [Inhibition 100 uM]
yes [Inhibition 100 uM]
Drug as victim
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Torasemide. A review of its pharmacological properties and therapeutic potential.
1991 Jan
Intraplatelet calcium levels in patients with acute renal failure before and after the administration of loop diuretics.
2001 Mar
Diuretics in the therapy of hypertension.
2002 Mar
[Which diuretic in heart failure? For the prognosis, they are not all equal].
2002 Mar 28
[Aggression to the immature kidney].
2002 Mar-Apr
Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV--efficacy and quality of life.
2003 Dec
[The place of diuretics in the treatment of chronic heart failure. Part I].
2005
Torsemide versus furosemide after continuous renal replacement therapy due to acute renal failure in cardiac surgery patients.
2005
Screening procedure for detection of diuretics and uricosurics and/or their metabolites in human urine using gas chromatography-mass spectrometry after extractive methylation.
2005 Aug
Functional characterization of human monocarboxylate transporter 6 (SLC16A5).
2005 Dec
Dose-independent pharmacokinetics of torasemide after intravenous and oral administration to rats.
2005 Jul
Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous torasemide in rats.
2005 Jul 14
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
Electrochemical characterisation of the human cytochrome P450 CYP2C9.
2005 May 15
Comparison of the urine acidification tests of torsemide vs furosemide in healthy volunteers.
2005 Nov
Pharmacological profile and therapeutic potential of BM-573, a combined thromboxane receptor antagonist and synthase inhibitor.
2005 Spring
Cardiomyopathy, familial dilated.
2006 Jul 13
Vasodilatory action of loop diuretics: a plethysmography study of endothelial function in forearm arteries and dorsal hand veins in hypertensive patients and controls.
2007 Feb
Secondary pulmonary hypertension: haemodynamic effects of torasemide versus furosemide.
2008
Torasemide, a long-acting loop diuretic, reduces the progression of myocarditis to dilated cardiomyopathy.
2008 Feb 26
Patents

Sample Use Guides

Congestive Heart Failure The usual initial dose is 10 mg or 20 mg of once-daily oral Demadex (Torasemide). If the diuretic response is inadequate, the dose should be titrated upward by approximately doubling until the desired diuretic response is obtained. Single doses higher than 200 mg have not been adequately studied. Chronic Renal Failure The usual initial dose of Demadex is 20 mg of once-daily oral Demadex. Hypertension The usual initial dose is 5 mg once daily. If the 5 mg dose does not provide adequate reduction in blood pressure within 4 to 6 weeks, the dose may be increased to 10 mg once daily.
Route of Administration: Oral
Isometric contraction induced by a submaximal concentration of Ang II (10(-7) mol/L) was reduced in a dose-dependent way by torasemide (IC(50)=0.5+/-0.04 umol/L) in cultured vascular smooth muscle cells (VSMCs) from spontaneously hypertensive rats..
Name Type Language
TORASEMIDE
INN   JAN   MART.   WHO-DD  
INN  
Preferred Name English
TORSEMIDE
MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF  
USAN  
Official Name English
LUPRAC
Brand Name English
TORSEMIDE [MI]
Common Name English
TORSEMIDE [USAN]
Common Name English
TORSEMIDE [VANDF]
Common Name English
TORSEMIDE [USP MONOGRAPH]
Common Name English
TORASEMIDE [JAN]
Common Name English
1-ISOPROPYL-3-((4-M-TOLUIDINO-3-PYRIDYL)SULPHONYL)UREA
Systematic Name English
TORSEMIDE [ORANGE BOOK]
Common Name English
TORASEMIDE [EP MONOGRAPH]
Common Name English
torasemide [INN]
Common Name English
Torasemide [WHO-DD]
Common Name English
SOAANZ
Brand Name English
TORSEMIDE [USP-RS]
Common Name English
3-PYRIDINESULFONAMIDE, N-(((1-METHYLETHYL)AMINO)CARBONYL)-4-((3-METHYLPHENYL)AMINO)-
Systematic Name English
AC4464
Code English
AC-4464
Code English
TORASEMIDE [MART.]
Common Name English
BM02.015
Code English
BM-02015
Code English
UPCARD
Brand Name English
TORASEMIDE ANHYDROUS [EMA EPAR VETERINARY]
Common Name English
BM-02.015
Code English
TORASEMIDE ANHYDROUS
Common Name English
TORSEMIDE [USP IMPURITY]
Common Name English
Classification Tree Code System Code
WHO-VATC QC03CA04
Created by admin on Mon Mar 31 18:00:09 GMT 2025 , Edited by admin on Mon Mar 31 18:00:09 GMT 2025
LIVERTOX 984
Created by admin on Mon Mar 31 18:00:09 GMT 2025 , Edited by admin on Mon Mar 31 18:00:09 GMT 2025
WHO-ATC C03CA04
Created by admin on Mon Mar 31 18:00:09 GMT 2025 , Edited by admin on Mon Mar 31 18:00:09 GMT 2025
NDF-RT N0000175366
Created by admin on Mon Mar 31 18:00:09 GMT 2025 , Edited by admin on Mon Mar 31 18:00:09 GMT 2025
NCI_THESAURUS C49184
Created by admin on Mon Mar 31 18:00:09 GMT 2025 , Edited by admin on Mon Mar 31 18:00:09 GMT 2025
EMA VETERINARY ASSESSMENT REPORTS UPCARD [AUTHORIZED]
Created by admin on Mon Mar 31 18:00:09 GMT 2025 , Edited by admin on Mon Mar 31 18:00:09 GMT 2025
NDF-RT N0000175590
Created by admin on Mon Mar 31 18:00:09 GMT 2025 , Edited by admin on Mon Mar 31 18:00:09 GMT 2025
Code System Code Type Description
RS_ITEM_NUM
1672304
Created by admin on Mon Mar 31 18:00:09 GMT 2025 , Edited by admin on Mon Mar 31 18:00:09 GMT 2025
PRIMARY
WIKIPEDIA
TORASEMIDE
Created by admin on Mon Mar 31 18:00:09 GMT 2025 , Edited by admin on Mon Mar 31 18:00:09 GMT 2025
PRIMARY
NCI_THESAURUS
C29506
Created by admin on Mon Mar 31 18:00:09 GMT 2025 , Edited by admin on Mon Mar 31 18:00:09 GMT 2025
PRIMARY
DRUG BANK
DB00214
Created by admin on Mon Mar 31 18:00:09 GMT 2025 , Edited by admin on Mon Mar 31 18:00:09 GMT 2025
PRIMARY
DAILYMED
W31X2H97FB
Created by admin on Mon Mar 31 18:00:09 GMT 2025 , Edited by admin on Mon Mar 31 18:00:09 GMT 2025
PRIMARY
CAS
56211-40-6
Created by admin on Mon Mar 31 18:00:09 GMT 2025 , Edited by admin on Mon Mar 31 18:00:09 GMT 2025
PRIMARY
DRUG CENTRAL
2708
Created by admin on Mon Mar 31 18:00:09 GMT 2025 , Edited by admin on Mon Mar 31 18:00:09 GMT 2025
PRIMARY
ChEMBL
CHEMBL1148
Created by admin on Mon Mar 31 18:00:09 GMT 2025 , Edited by admin on Mon Mar 31 18:00:09 GMT 2025
PRIMARY
EVMPD
SUB11195MIG
Created by admin on Mon Mar 31 18:00:09 GMT 2025 , Edited by admin on Mon Mar 31 18:00:09 GMT 2025
PRIMARY
MESH
C026116
Created by admin on Mon Mar 31 18:00:09 GMT 2025 , Edited by admin on Mon Mar 31 18:00:09 GMT 2025
PRIMARY
IUPHAR
7312
Created by admin on Mon Mar 31 18:00:09 GMT 2025 , Edited by admin on Mon Mar 31 18:00:09 GMT 2025
PRIMARY
CHEBI
9637
Created by admin on Mon Mar 31 18:00:09 GMT 2025 , Edited by admin on Mon Mar 31 18:00:09 GMT 2025
PRIMARY
RXCUI
38413
Created by admin on Mon Mar 31 18:00:09 GMT 2025 , Edited by admin on Mon Mar 31 18:00:09 GMT 2025
PRIMARY RxNorm
INN
3938
Created by admin on Mon Mar 31 18:00:09 GMT 2025 , Edited by admin on Mon Mar 31 18:00:09 GMT 2025
PRIMARY
EPA CompTox
DTXSID2023690
Created by admin on Mon Mar 31 18:00:09 GMT 2025 , Edited by admin on Mon Mar 31 18:00:09 GMT 2025
PRIMARY
SMS_ID
100000090291
Created by admin on Mon Mar 31 18:00:09 GMT 2025 , Edited by admin on Mon Mar 31 18:00:09 GMT 2025
PRIMARY
PUBCHEM
41781
Created by admin on Mon Mar 31 18:00:09 GMT 2025 , Edited by admin on Mon Mar 31 18:00:09 GMT 2025
PRIMARY
MERCK INDEX
m10981
Created by admin on Mon Mar 31 18:00:09 GMT 2025 , Edited by admin on Mon Mar 31 18:00:09 GMT 2025
PRIMARY Merck Index
LACTMED
Torsemide
Created by admin on Mon Mar 31 18:00:09 GMT 2025 , Edited by admin on Mon Mar 31 18:00:09 GMT 2025
PRIMARY
FDA UNII
W31X2H97FB
Created by admin on Mon Mar 31 18:00:09 GMT 2025 , Edited by admin on Mon Mar 31 18:00:09 GMT 2025
PRIMARY